The pathogen reduction systems works on the principal of exposing the plasma to the ultraviolet rays in presence of photosensitizer to act as pathogen inactivator. The pathogen reduction systems are distinctive artificially isolated for the segregations of blood components to Tarate factor plasma.
The action is assayed by the plasmas test and the value are depicted after the photosensitizer process. The pathogen reduction systems are manufactured to withstand infectious pathogens of different genera. The inactivation strength of the photosensitizer varies from product to product.
Primarily the products are for blood infection disease applications. The Pathogen Reduction Systems is advanced product offering in the management of the blood transfusion and pathogen inactivation. The advancement in inaction or component in Pathogen Reduction Systems is anticipated to offer new growth opportunity in the Pathogen Reduction Systems market.
The growing demand for blood components and blood in various surgeries and interventions coupled with high prevalence of the infectious disease is anticipated to lure new manufacturers in the pathogen reduction systems market.
Deferral procedures and donor screening in addition to nucleic acid and serologic testing facilitated the initiative for creating blood a safer product for transfusion with the utilization of pathogen reduction systems
Increase in demand for plasma proteins, rising investment in innovation, and continuously increasing prevalence of infectious diseases across the globe are significant factors that are projected to drive the global pathogen reduction systems market. The pathogen reduction systems industry has been investing in research and development of new pathogen reduction systems leading to innovative treatments for the benefits of blood receiver.
For example, in 2014, the leading manufacturer Cerus Corporation developed and introduced the first pathogen reduction system INTERCEPT and invested US$ 151 Mn in clinical trials to grow its development capabilities for pathogen reduced plasma.
The investment is anticipated to increase the product portfolio of manufacturing pathogen reduction systems and purification of several plasma groups. Moreover, the rising investments in innovation propels the technological advancements in efficient and cost-effective procedures for fractionating plasma from blood, which in turn boost the pathogen reduction systems market.
However, constantly rising product launch and product penetration by key manufacturers. Additionally fair reimbursement issues are major aspects restraining the growth of the global pathogen reduction systems market.
The Pathogen Reduction Systems market displays similar to oligopolistic competition nature. Leading players in the Pathogen Reduction Systems market are largely working on research and development of advanced plasma inhibitor factor. As per the data from WHO, Thalassemia have high prevalence rate in low income countries primarily affecting the child at birth.
The blood born infection during transfusion are common in all ethnic group and races. The Semi-automated pathogen reduction system segment is anticipated to dominate the market, due to the rising prevalence of blood infection such as zika virus, Hepatitis A virus. Invasive surgeries performed in the developing and developed countries are anticipated to offer new growth opportunity for the Pathogen Reduction Systems market.
As per the data from National institute on blood, heart and lungs around 6 to 6.5 million blood transfusion are conducted in the US only. The manufacturer in the pathogen reduction systems are contributing to the higher safety protocols for the pathogen reduction in the blood.
The Global Pathogen Reduction Systems market is segmented into the following regions - North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East & Africa. North America is leading regional market for pathogen reduction systems due to high product adoption, high range of products availability and developed health care infrastructure in the region.
In East Asia, China is prominent Pathogen Reduction Systems market due to widespread use of Pathogen Reduction Systems additionally presence of manufacturing facilities. Latin America Pathogen Reduction Systems market is anticipated to show low growth rate owing to use of substitutes methods for pathogen reduction.
South Asia is projected to show considerably higher growth rate reasoning to the development of advanced medical technologies. Growth in Middle East and Africa is static as lower penetration of the key players in the regions.
Examples of some of the key participants in the Pathogen Reduction Systems market are
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections using a suitable set of assumptions and methodologies.
The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Based on product type Pathogen Reduction Systems market is further segmented into:
Based on Application Pathogen Reduction Systems market is further segmented into:
Based on End User Pathogen Reduction Systems market is further segmented into:
Explore Similar Insights
Pathogen Reduction Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
